
Oncology NEWS International
- Oncology NEWS International Vol 15 No 9
- Volume 15
- Issue 9
Phase I/II Trial of AGS-003
Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
DURHAM, North CarolinaArgos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
Articles in this issue
over 19 years ago
Exjade Gains Approval in EUover 19 years ago
President's Cancer Panel Assesses Progress in Two Areasover 19 years ago
Cognitive Rx Reduces Depression in Breast Ca Ptsover 19 years ago
Nurses Develop Evidence-Based Guidelines for Mucositisover 19 years ago
Anastrozole Therapy for Breast Cancer Affects Bone Healthover 19 years ago
Is Demand for Trial Subjects Outpacing Supply?over 19 years ago
Postchemo Disappearance of Liver Mets Doesn't Mean Cureover 19 years ago
Aromasin-Related Bone Loss Affected by Vitamin D LevelsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.

















































































